Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.

Mini reviews in medicinal chemistry - 1 Mar 2004

Cowan-Jacob Sandra W, Guez Valerie, Fendrich Gabriele, Griffin James D, Fabbro Doriano, Furet Pascal, Liebetanz Janis, Mestan Jürgen, Manley Paul W

Abstract excerpt

Following the paradigm set by STI571, protein tyrosine kinase inhibitors are emerging as a promising class of drugs, capable of modulating intracellular signaling and demonstrating therapeutic potential for the treatment of proliferative diseases. Although the majority of chronic phase CML patien...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, abl

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Share to Protein-Tyrosine Kinases

Share to Pyrimidines

Source

Identifiers

PMID: 15032675
DOI: 10.2174/1389557043487321

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-15032675-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.PMID 15032675Read ↗

Molecular mechanisms of resistance to STI571 in chronic myeloid leukemiaSemantic proximity Read ↗

[STI571: a summary of targeted therapy].Semantic proximity Read ↗

[Novel inhibitors of Bcr-Abl].Semantic proximity Read ↗

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.Semantic proximity Read ↗

Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571Semantic proximity Read ↗

Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia.Semantic proximity Read ↗

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.Semantic proximity Read ↗

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationSemantic proximity Read ↗

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loopSemantic proximity Read ↗

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.Semantic proximity Read ↗

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.Semantic proximity Read ↗

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.